vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PAMT CORP (PAMT). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $141.3M, roughly 2.0× PAMT CORP). PAMT CORP runs the higher net margin — -20.7% vs -45.7%, a 25.0% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -15.1%). PAMT CORP produced more free cash flow last quarter ($-25.0M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -12.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GH vs PAMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $141.3M |
| Net Profit | $-128.5M | $-29.3M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | -27.0% |
| Net Margin | -45.7% | -20.7% |
| Revenue YoY | 39.4% | -15.1% |
| Net Profit YoY | -15.8% | 7.4% |
| EPS (diluted) | $-1.01 | $-1.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $141.3M | ||
| Q3 25 | $265.2M | $150.3M | ||
| Q2 25 | $232.1M | $151.1M | ||
| Q1 25 | $203.5M | $155.3M | ||
| Q4 24 | $201.8M | $166.5M | ||
| Q3 24 | $191.5M | $182.6M | ||
| Q2 24 | $177.2M | $182.9M | ||
| Q1 24 | $168.5M | $182.6M |
| Q4 25 | $-128.5M | $-29.3M | ||
| Q3 25 | $-92.7M | $-5.6M | ||
| Q2 25 | $-99.9M | $-9.6M | ||
| Q1 25 | $-95.2M | $-8.1M | ||
| Q4 24 | $-111.0M | $-31.6M | ||
| Q3 24 | $-107.8M | $2.4M | ||
| Q2 24 | $-102.6M | $-2.9M | ||
| Q1 24 | $-115.0M | $281.0K |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | -27.0% | ||
| Q3 25 | -37.3% | -3.8% | ||
| Q2 25 | -45.9% | -7.3% | ||
| Q1 25 | -54.6% | -5.9% | ||
| Q4 24 | -62.4% | -22.6% | ||
| Q3 24 | -61.3% | 1.3% | ||
| Q2 24 | -56.8% | -0.4% | ||
| Q1 24 | -59.2% | -0.4% |
| Q4 25 | -45.7% | -20.7% | ||
| Q3 25 | -35.0% | -3.7% | ||
| Q2 25 | -43.0% | -6.4% | ||
| Q1 25 | -46.8% | -5.2% | ||
| Q4 24 | -55.0% | -19.0% | ||
| Q3 24 | -56.3% | 1.3% | ||
| Q2 24 | -57.9% | -1.6% | ||
| Q1 24 | -68.2% | 0.2% |
| Q4 25 | $-1.01 | $-1.38 | ||
| Q3 25 | $-0.74 | $-0.27 | ||
| Q2 25 | $-0.80 | $-0.46 | ||
| Q1 25 | $-0.77 | $-0.37 | ||
| Q4 24 | $-0.90 | $-1.44 | ||
| Q3 24 | $-0.88 | $0.11 | ||
| Q2 24 | $-0.84 | $-0.13 | ||
| Q1 24 | $-0.94 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $83.7M |
| Total DebtLower is stronger | $1.5B | $333.9M |
| Stockholders' EquityBook value | $-99.3M | $210.5M |
| Total Assets | $2.0B | $697.9M |
| Debt / EquityLower = less leverage | — | 1.59× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $83.7M | ||
| Q3 25 | $580.0M | $115.6M | ||
| Q2 25 | $629.1M | $117.3M | ||
| Q1 25 | $698.6M | $102.7M | ||
| Q4 24 | $525.5M | $110.7M | ||
| Q3 24 | $585.0M | $92.3M | ||
| Q2 24 | $933.7M | $114.0M | ||
| Q1 24 | $1.0B | $125.8M |
| Q4 25 | $1.5B | $333.9M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $325.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $210.5M | ||
| Q3 25 | $-354.5M | $239.5M | ||
| Q2 25 | $-305.5M | $244.9M | ||
| Q1 25 | $-250.8M | $269.6M | ||
| Q4 24 | $-139.6M | $277.5M | ||
| Q3 24 | $-60.1M | $308.9M | ||
| Q2 24 | $-1.6M | $306.7M | ||
| Q1 24 | $68.3M | $314.6M |
| Q4 25 | $2.0B | $697.9M | ||
| Q3 25 | $1.3B | $715.2M | ||
| Q2 25 | $1.3B | $707.9M | ||
| Q1 25 | $1.3B | $712.6M | ||
| Q4 24 | $1.5B | $741.7M | ||
| Q3 24 | $1.5B | $756.7M | ||
| Q2 24 | $1.6B | $733.5M | ||
| Q1 24 | $1.7B | $746.4M |
| Q4 25 | — | 1.59× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-5.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $-25.0M |
| FCF MarginFCF / Revenue | -19.3% | -17.7% |
| Capex IntensityCapex / Revenue | 9.9% | 13.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-23.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-5.8M | ||
| Q3 25 | $-35.4M | $5.9M | ||
| Q2 25 | $-60.3M | $12.2M | ||
| Q1 25 | $-62.7M | $5.0M | ||
| Q4 24 | $-64.5M | $15.2M | ||
| Q3 24 | $-51.1M | $15.5M | ||
| Q2 24 | $-94.0M | $18.7M | ||
| Q1 24 | $-30.3M | $9.6M |
| Q4 25 | $-54.2M | $-25.0M | ||
| Q3 25 | $-45.8M | $2.5M | ||
| Q2 25 | $-65.9M | $5.9M | ||
| Q1 25 | $-67.1M | $-6.8M | ||
| Q4 24 | $-83.4M | $-39.9M | ||
| Q3 24 | $-55.3M | $-33.6M | ||
| Q2 24 | $-99.1M | $4.1M | ||
| Q1 24 | $-37.2M | $-12.2M |
| Q4 25 | -19.3% | -17.7% | ||
| Q3 25 | -17.3% | 1.7% | ||
| Q2 25 | -28.4% | 3.9% | ||
| Q1 25 | -33.0% | -4.4% | ||
| Q4 24 | -41.3% | -24.0% | ||
| Q3 24 | -28.9% | -18.4% | ||
| Q2 24 | -55.9% | 2.2% | ||
| Q1 24 | -22.1% | -6.7% |
| Q4 25 | 9.9% | 13.6% | ||
| Q3 25 | 3.9% | 2.3% | ||
| Q2 25 | 2.4% | 4.2% | ||
| Q1 25 | 2.2% | 7.6% | ||
| Q4 24 | 9.4% | 33.1% | ||
| Q3 24 | 2.2% | 26.9% | ||
| Q2 24 | 2.9% | 8.0% | ||
| Q1 24 | 4.1% | 12.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.44× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 34.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
